NCT01046916View on ClinicalTrials.gov

Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

January 31, 2013

Study Completion Date

March 31, 2013

Conditions
Prostate Cancer
Interventions
DRUG

TAK-700

TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule

Trial Locations (3)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

53705

University of Wisconsin Hospitals and Clinics, Madison

97239

Oregon Health and Sciences University, Portland

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY